Roche's Divarasib Shows Statistically Significant Progression-Free And Overall Survival Gains Versus Sotorasib Or Adagrasib In NSCLC Study
هوفمان-لا روش
هوفمان-لا روش ADR
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer
- Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed
- Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population
- Data will be submitted to health authorities and presented at an upcoming medical meeting